other material
confidence high
sentiment positive
materiality 0.85
Intellia reports NTLA-2002 Phase 1 data: 95% reduction in HAE attacks; 9/10 attack-free
Intellia Therapeutics, Inc.
- Single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate across all 10 patients.
- Nine of 10 patients remained completely attack-free following the 16-week primary observation period.
- All 6 patients who discontinued long-term prophylaxis reported no attacks since stopping.
- NTLA-2002 well-tolerated; most common adverse events were mild infusion reactions and fatigue.
- Global pivotal Phase 3 study planned for H2 2024 subject to regulatory feedback.